Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $123.22 Average PT from Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has earned a consensus rating of “Hold” from the twenty ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $123.22.

Several equities research analysts have issued reports on the stock. Oppenheimer dropped their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. BTIG Research dropped their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Wells Fargo & Company lifted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Robert W. Baird dropped their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th.

Zimmer Biomet Price Performance

ZBH stock opened at $110.23 on Friday. The firm has a 50 day moving average of $106.79 and a 200-day moving average of $109.78. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a 12 month low of $101.47 and a 12 month high of $133.90. The firm has a market capitalization of $21.94 billion, a P/E ratio of 20.96, a price-to-earnings-growth ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period last year, the business earned $1.65 earnings per share. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. As a group, sell-side analysts predict that Zimmer Biomet will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Dunhill Financial LLC raised its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter worth $28,000. Crewe Advisors LLC bought a new position in Zimmer Biomet in the 1st quarter worth $31,000. Bangor Savings Bank bought a new position in Zimmer Biomet in the 3rd quarter worth $31,000. Finally, Family Firm Inc. bought a new position in shares of Zimmer Biomet in the 2nd quarter worth about $33,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.